Bristol Myers Squibb Co.’s treatment for schizophrenia failed in a study designed to expand its use, denting the company’s ...

Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly ...

(Reuters) -Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a ...

Compared with placebo, xanomeline/trospium as an add-on to atypical antipsychotics has not reached the threshold for a ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

Are substance-induced psychosis and primary psychosis fundamentally different? And if they are, does it matter?

The new data – from the ARISE trial – found that Cobenfy wasn't statistically better than placebo at improving the widely ...

Neurocrine Biosciences' valbenazine shows promise as an adjunctive therapy for Schizophrenia, with phase 3 data expected in ...

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is ...

Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily ...

Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point ...

The company was studying the drug as an adjunctive treatment to atypical antipsychotics in adults with schizophrenia, a mental health condition that affects how people think, feel and behave.